Geographic Atrophy (GA) Market Trends and Overview

Geographic Atrophy (GA) is a progressive and irreversible form of age-related macular degeneration (AMD) that leads to the loss of central vision. As the population ages, the prevalence of GA is expected to rise, thereby driving the growth of the GA market.

One key aspect of the GA market is the development and commercialization of innovative therapies. Currently, there are no approved treatments for GA, making it an area with significant unmet medical needs. However, several pharmaceutical companies are actively engaged in research and clinical trials to develop potential therapies targeting GA.

The market for GA treatments is expected to witness substantial growth as these novel therapies progress through clinical trials and receive regulatory approvals. These treatments aim to slow down or halt the progression of GA by targeting specific mechanisms involved in its pathogenesis. Some promising approaches include complement inhibitors, anti-inflammatory agents, neuroprotective drugs, and gene therapies.

Get Free Sample Report @

In addition to therapeutic interventions, diagnostic tools play a crucial role in managing GA. Early detection and accurate monitoring Early detection and accurate monitoring of GA are essential for timely intervention and effective management of the disease. Diagnostic tools such as retinal imaging techniques, visual field tests, and genetic testing can aid in the early identification of GA and help track its progression over time. These tools enable healthcare professionals to assess the effectiveness of therapeutic interventions and make informed decisions regarding treatment adjustments. By combining therapeutic interventions with precise diagnostic tools, healthcare providers can optimize patient outcomes and improve the quality of life for individuals living with GA.


By Age Group

  • Above 60 Years
  • Above 75 Years

By Diagnosis

  • Fundus Autofluorescence (FAF)
  • Optical Coherence Tomography Angiography (OCT-A)
  • Multifocal Electroretinography (mfERG)

By Therapeutic Agents Clinical Phase

  • Late-stage (Phase III)
  • Phase II
  • Phase I
  • Pre-clinical stage & Discovery candidates


The Key players are AstraZeneca plc, Gyroscope Therapeutics Limited, Hoffmann-La Roche AG, Apellis Pharmaceuticals, Inc., Iveric Bio, Gensight Biologics SA, Stealth BioTherapeutics, Allegro Ophthalmics, LLC, Regenerative Patch Technologies, LLC, Genentech, Inc., Alkeus Pharmaceuticals, Inc., NGM Biopharmaceuticals Inc., Hemera Biosciences LLC, and Other Players.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

[email protected],

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),